US2015238633A1PendingUtilityA1
Antibody drug conjugates (adc) that bind to 158p1d7 proteins
Est. expiryAug 23, 2032(~6.1 yrs left)· nominal 20-yr term from priority
C07K 16/3023A61P 35/00A61K 45/06A61K 47/6813C07K 16/18C07K 16/3015A61K 47/6855C07K 16/30C07K 2317/21C07K 16/3038C07K 2317/77C07K 2317/56C07K 2317/92A61K 47/6851C07K 16/3053A61K 47/6817A61K 47/6861C07K 2317/76C07K 2317/73A61K 47/6849A61K 47/6865A61K 2039/505A61K 47/6811A61K 47/6859A61K 47/6857A61K 39/395A61K 47/48415A61K 47/48569A61K 47/68031
61
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Antibody drug conjugates (ADC's) that bind to 158P1D7 protein and variants thereof are described herein. 158P1D7 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in glioblastoma, lung cancer, bladder cancer, and breast cancer. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.
Claims
exact text as granted — not AI-modifiedWe claim:
1 . An antibody drug conjugate comprising an antibody or antigen binding fragment to monomethyl auristatin E (MMAE), wherein the antibody or fragment comprises the heavy chain variable region consisting of the amino acid sequence ranging from 1 st Q to the 120 th S of SEQ ID NO: 7 and the light chain variable consisting of the amino acid sequence ranging from 1 st D to the 113 th R SEQ ID NO: 8.Join the waitlist — get patent alerts
Track US2015238633A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.